| Name | Title | Contact Details |
|---|
Data Health USA is a Ashland, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RaNA Therapeutics is pioneering the discovery of a new class of RNA-targeted medicines that selectively activate protein expression within the body`s own cells. By targeting specific genes, RaNA`s novel drugs work epigenetically to precisely upregulate the expression of beneficial proteins in order to treat or prevent disease. The company`s leadership leverages preeminent founders and advisors in the field, and the strength of its fundamental patents, technology, and know-how that underlie the discovery and development of therapeutics that selectively activate RNA. RaNA is applying its proprietary technology to rapidly advance a pipeline of novel drugs for diverse therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, inflammation, oncology, metabolic diseases and neurodegenerative diseases.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
Athenahealth is a leading provider of cloud-based services for electronic health records (EHR), revenue cycle management and medical billing, patient engagement, care coordination, and population health management, as well as Epocrates and other point-of-care mobile apps.
Texas Medical Association was organized by 35 physicians in 1853 to serve the people of Texas in matters of medical care, prevention and cure of disease, and the improvement of public health. Today, with more than 56,000 physician and medical student members, TMA is the nation`s largest state medical society. TMA`s key objective is to improve the health of all Texans.